Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Fate Therapeutics, Inc.NASDAQ: FATE

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow declines year over year

Q1 FY2026 free cash flow of $31.06M (cash outflow) fell 11.3% year over year, ahead of the -13.6% change in trailing-twelve-month free cash flow. Sequentially, it rose 26.7% from the prior quarter. Over 3 fiscal years it compounded at -26.6% a year.

Context

  • Free cash flow amounted to 1685.8% of revenue in FY2025, up 779.0 pp from a year earlier.
  • Free cash flow grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -11.3% holds above the trailing-twelve-month pace of -13.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$31.06M+26.7% QoQ
Last fiscal yearDec 2025
-$112.04M-9.4% YoY
LTMMar 2026
-$108.09M-13.6% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.3%——
1 year-9.4%——
3-year CAGR-26.6%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(112.04M) USD
Year-over-year change
+9.4%

Free Cash Flow vs competitors

How FATE compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.6% is the 6th highest of 10, against a peer median of -8.4%.
  • Free cash flow amounts to 1711.4% of revenue for FATE, versus a peer median of 601.1%.
FATE Competitors
Free Cash Flow for FATE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$173.2M USD-24.7%+96.0%940.4%
VORVor Biopharma Inc.LTM Mar 2026$150.65M USD+49.7%+15.3%—
FATEFate Therapeutics, Inc.LTM Mar 2026$108.09M USD-13.6%-26.6%1711.4%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$105.55M USD+2.9%+48.5%—
NKTXNkarta, Inc.LTM Mar 2026$88.39M USD-16.3%-4.8%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$83.57M USD-18.6%-25.7%—
PEPGPepGen Inc.LTM Mar 2026$77.27M USD-7.3%+9.1%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$73.65M USD+46.6%+19.8%—
MOLNMolecular Partners AGLTM Mar 2026CHF 54.13M CHF-8.4%——
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$43.78M USD-58.6%-13.4%261.8%
Peer median (excluding FATE) —-8.4%+12.2%601.1%

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
Deferred Income Tax00000
Stock-Based Compensation54.36M78.73M43.46M41.5M24.92M
Change in Working Capital2.1M(34.71M)19.18M(1.96M)(3.74M)
Accounts Receivables(3.16M)(29.8M)36.65M(1.11M)2.62M
Inventory00000
Accounts Payables014.25M(28.94M)(1.66M)(9.03M)
Other Working Capital5.26M(19.16M)11.47M816K2.66M
Other Non-Cash Items(13.03M)(24.27M)(52.26M)4.89M(247K)
Operating Cash Flow(162.87M)(248.21M)(132.26M)(122.87M)(106.08M)
Capital Expenditures(50.7M)(35.57M)(6.15M)(730K)(5.95M)
Acquisitions (Net)0000362K
Purchases of Investments(968.16M)(404.8M)(358.81M)(317.75M)(195.14M)
Sales of Investments694.84M607.11M477.63M330.7M311.9M
Other Investing Activities00000
Investing Cash Flow(324.02M)166.75M112.67M12.22M111.17M
Debt Repayment00000
Common Stock Issued411.74M9.21M85K94.82M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities41.39M005.07M5.49M
Financing Cash Flow453.13M9.21M85K99.89M5.49M
Effect of Forex Changes0050K4.95M0
Net Change in Cash(33.76M)(72.25M)(19.46M)(5.81M)10.57M
Free Cash Flow(213.57M)(283.77M)(138.42M)(123.6M)(112.04M)

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.